To identify risk variants for multiple myeloma, we conducted a genome-wide association study of 1,675 individuals with multiple myeloma and 5,903 control subjects. We identified risk loci for multiple myeloma at 3p22.1 (rs1052501 in ULK4; odds ratio (OR) = 1.32; P = 7.47 × 10 −9 ) and 7p15.3 (rs4487645, OR = 1.38; P = 3.33 × 10 −15 ). In addition, we observed a promising association at 2p23.3 (rs6746082, OR = 1.29; P = 1.22 × 10 −7 ). Our study identifies new genomic regions associated with multiple myeloma risk that may lead to new etiological insights.
To identify risk variants for multiple myeloma, we conducted a genome-wide association study of 1,675 individuals with multiple myeloma and 5,903 control subjects. We identified risk loci for multiple myeloma at 3p22.1 (rs1052501 in ULK4; odds ratio (OR) = 1.32; P = 7.47 × 10 −9 ) and 7p15.3 (rs4487645, OR = 1.38; P = 3.33 × 10 −15 ). In addition, we observed a promising association at 2p23.3 (rs6746082, OR = 1.29; P = 1.22 × 10 −7 ). Our study identifies new genomic regions associated with multiple myeloma risk that may lead to new etiological insights.
Multiple myeloma is a malignancy of the plasma cells that primarily localize to the bone marrow 1 . In the United States, ~16,000 indivi duals are diagnosed each year with this disease and ~11,000 die from it 2 . Monoclonal gammopathy of undetermined significance (MGUS; a premalignant clone of plasma cells producing a mono clonal paraprotein) is present in ~2% of individuals older than 50 years, and the risk of progressing to multiple myeloma increases by 1% each year 3 . The increased risk of multiple myeloma in the relatives of individuals with MGUS is consistent with MGUS being a marker of genetic susceptibility 4 . To date, no lifestyle or environmental exposure factors have been consistently linked to an increased risk of multi ple myeloma or MGUS. On the basis of the hypothesis that part of the two to fourfold elevated risk of multiple myeloma in relatives of individuals with multiple myeloma 5 is a consequence of the co inheritance of multiple lowrisk variants, we conducted two genome wide association studies (GWAS) of multiple myeloma.
The two GWAS were conducted in the UK and Germany. Genotyping of both series of individuals with multiple myeloma (cases) was conducted using Illumina OmniExpress BeadChips.
Cases for the UK GWAS comprised 1,371 individuals recruited through the UK Medical Research Council (MRC) MyelomaIX trial 6 . Genotype frequencies were compared with publicly accessible genotype data generated by the UK Wellcome Trust Case Control Consortium 2 (WTCCC2) study of 2,699 individuals from the 1958 British Birth Cohort (known as 58C) 7 and 2,501 individuals from the UK Blood Service (UKBS) collections that had been genotyped using Illumina Human 1.2MDuo Custom_v1 Array BeadChips (see Online Methods). The German GWAS performed genotyping of 384 multiple myeloma cases recruited through the Heidelberg University Clinic. Genotype frequencies were compared with publicly accessible genotype data generated by the HeinzNixdorf Recall (HNR) study of 704 individuals 8 from the German popula tion who had been genotyped using Illumina Human Omni1Quad BeadChips (see Online Methods).
Genotype data from the two GWAS were filtered on the basis of prespecified quality control measures (see Online Methods). Individual SNPs were excluded from further analysis if they showed deviation from HardyWeinberg equilibrium with P < 1.0 × 10 −6 in controls, an individual SNP genotype yield <95% or a minor allele frequency <1%. After this filtering, 422,839 autosomal SNPs common to both casecontrol series remained for further study. A total of 80 case samples were removed during quality control processing for several reasons, including if sample genotyping failed, if samples belonged to pairs of unknown duplicates or closely related individuals or if individuals were of different ancestry from the cohort of Utah residents of Northern and Western European descent (CEU) ( Supplementary Figs. 1 and 2) .
Prior to undertaking the metaanalysis of the two GWAS, we searched for potential errors and biases in the data sets.
Quantilequantile plots of genomewide χsquared values showed that there was minimal inflation of the test statistics, indicating that substantial cryptic population substructuring or differential geno type calling between cases and controls was unlikely in either GWAS (genomic control inflation factor 9 λ GC = 1.033 and 1.059 in the UK and German GWAS, respectively; Supplementary Fig. 3 ). To fully examine the effects of population substructure on our findings, we performed principalcomponents analysis using the EIGENSTRAT 10 software (λ corrected = 1.010 and 1.005 in the UK and German GWAS, respectively; Supplementary Fig. 3 ).
Using data from all cases and controls from both series, we derived the combined OR and confidence interval (CI) for each SNP under a fixedeffects model along with the associated P value 11 . In the com bined analysis, 19 SNPs, which map to three genomic regions, showed evidence for an association with multiple myeloma at P combined < 5.0 × 10 −7 and with evidence for association at P < 0.05 in both data sets ( Supplementary Table 1 ). We successfully genotyped the most highly associated SNPs mapping to the three regions in 169 multiple myeloma cases recruited through the UK MRC MyelomaVII trial (see Online Methods). For controls, we used Illumina Hap550K BeadChip genotype data generated for 927 healthy individuals from the UK as part of a study of colorectal cancer we had previously con ducted 12 . In combined analysis, the association of the rs1052501 SNP at 3p22.1 and rs1052501 at 7p15.3 with multiple myeloma attained genomewide significance (P = 7.47 × 10 −9 and 3.33 × 10 −15 , respec tively; Table 1 ).
The rs1052501 SNP localizes to exon 17 of the ULK4 gene (encod ing unc51-like kinase 4) (41,900,402 bp) within a 516kb region of linkage disequilibrium (LD) at 3p22.1 (Fig. 1) . The GtoA tran sition at rs1052501 results in an alanine to threonine alteration at amino acid 542, which is predicted to be tolerated or benign by the in silico SIFT and Polyphen algorithms, respectively. ULK4 encodes a serine/threonine protein kinase, and the Atg1ULK complex is a key regulator of mTORmediated autophagy 13 , although it has not thus far been directly implicated in multiple myeloma pathogenesis. However, autophagy genes are increasingly considered to be tumor suppressors 14 , and mTOR regulation notably represents an important therapeutic target in myelomatous plasma cells 15 . In addition to ULK4, the region of extensive LD encompasses the 5′ end of TRAK1 (trafficking protein, kinesinbinding 1; MIM 608112), which has a crucial role in regulating the endocytic trafficking of the GABA(A) receptors.
The rs4487645 SNP maps to intron 80 of the DNAH11 gene (dynein, axonemal, heavy chain 11; MIM 603339) at 7p15.3 (21,904,765 bp; Fig. 1 ). DNAH11 encodes a dynein heavy chain microtubule dependent ATPase motor, which is involved in respiratory cilia move ment. Germline DNAH11 mutations cause Kartagener syndrome (characterized by situs inversus totalis and primary ciliary dyskinesia). The 88kb region of LD to which rs4487645 maps also contains the 3′ end of the CDCA7L gene (cell division cycle-associated 7like; MIM 609685) ( Fig. 1) . Deregulation of MYC typifies plasma cell neo plasms 16, 17 . CDCA7L therefore represents an attractive candidate for the functional basis of the rs4487645 association because CDCA7L is a MYCinteracting protein, acts as a binding partner of p75 and potentiates the MYCmediated transformation events 18, 19 .
In addition to the 3p22.1 and 7p15.3 loci, we identified a promising association for rs6746082 at 2p23.3, but this association did not reach genomewide significance (P = 1.22 × 10 −7 ). rs6746082 localizes to intron 12 of DTNB (25,512,748 bp; Fig. 1 ) within a 256kb region of LD on 2p23.3. DTNB (MIM 602415) encodes βdystrobrevin, a component of the dystrophinassociated protein complex that is abundantly expressed in the brain and other tissues but not in muscle. Alternatively spliced transcript variants encoding different DTNB isoforms exist, but none have thus far been implicated in the biology of multiple myeloma 20 .
Elucidation of the basis of the 2p23.3, 3p22.1 and 7p15.3 associa tions will require finemapping and functional analyses. However, to explore these regions further, we imputed unobserved genotypes in the UK and German GWAS cases and controls using data from HapMap Phase 3 and the 1000 Genomes Project (see Online Methods). This analysis did not provide substantive evidence for a stronger associa tion at any of the three regions than those detected for rs4487645, rs1052501 or rs6746082 ( Fig. 1 and Supplementary Table 2 ). To examine whether any directly genotyped or imputed SNPs were l e t t e r s l e t t e r s located within a putative transcription factor-binding site or enhancer element, we conducted a bioinformatic search of the region of associa tion using the TRANSFAC Matrix Database 21 and PReMod 22 software. These analyses did not provide evidence for rs4487645, rs1052501, rs6746082 or any closely correlated SNPs mapping within a known or predicted transcription regulatory region ( Supplementary Table 2 ).
To explore whether the associations of rs4487645, rs1052501 and rs6746082 with multiple myeloma reflect cisacting regulatory effects on their surrounding genes, DNAH11 or CDCA7L, ULK4 or TRAK1 and DTNB, respectively, we examined mRNA expression in the plasma cells of 191 multiple myeloma cases using Human Genome U133 Plus 2.0 arrays (Affymetrix) 23 and 90 EBVinfected lymphoblastoid cell lines using Sentrix Human6 Expression BeadChips (Illumina) 24, 25 . There was no consistent statistically significant relationship between rs4487645, rs1052501 or rs6746082 and expression of their surround ing genes after adjustment for multiple testing ( Supplementary  Fig. 4) . These results do not preclude the possibility of subtle effects of genotype on gene expression with a cumulative longterm impact, as we could only detect >5% difference in expression by genotype with 80% power, and, furthermore, levels of RNA at a single time point may not adequately capture the impact of differential expression on tumor development.
Multiple myeloma occurs predominantly in males. We assessed the relationship between sex, age at diagnosis and the rs4487645, rs1052501 and rs6746082 SNPs by caseonly analysis using data from all series ( Supplementary Table 3 ). The association with multiple myeloma was not related to age or sex ( Supplementary Table 3 ). Several subtypes of multiple myeloma have been recognized that have unique clinicopathological phenotypes 26 . Hierarchically, multiple myeloma can be divided into hyperdiploid and non hyperdiploid subtypes 27, 28 . The latter is primarily composed of cases harboring IGH translocations (t(11;14)(q13;q32), t(4;14)(p16;q32) and t(14;16)(q32;q23)) and is typified by more aggressive disease. Trisomies and a more indolent form of the disease characterize hyper diploid multiple myeloma 26, 29 . Caseonly analysis provided no evi dence for subtypespecific associations at these SNPs after adjustment for multiple testing, consistent with the risk variants having general effects on multiple myeloma (Supplementary Table 3 ).
The risks for multiple myeloma conferred by rs4487645, rs1052501 and rs6746082 are modest, collectively accounting for only ~4% of the familial risk of multiple myeloma. However, the carrier frequen cies of risk alleles are high in the European population; therefore, the loci make a significant contribution to the development of multiple myeloma in terms of the attributable fraction in the popula tion, underlying ~37% of cases. It will be intriguing to explore how our findings translate to nonEuropean populations, which have a lower incidence of MGUS and multiple myeloma 30 . As the frequen cies of rs4487645, rs1052501 and rs6746082 genotypes in the Han Chinese in Beijing (CHB), Japanese in Tokyo (JPT) and Yoruba in Ibadan (YRI) populations are substantially different from the CEU population, it is possible that variations within 2p23.3, 3p22.1 and 7p15.3 contribute, in part, to differences in disease incidence.
Our findings provide evidence that common genetic variation influences multiple myeloma risk. These findings, in conjunction with recent observations from GWAS of Hodgkin's lymphoma 31 and chronic lymphocytic leukemia 32 , raise the possibility that genetically determined dysregulation of MYC may be a common mechanism underlying the predisposition to hematological malignancies of the Bcell lineage. Given the modest size of our study and the evidence for an overrepresentation of association signals after excluding SNPs mapping to the LD regions of association at 2p23.3, 3p22.1 and 7p15.3 (Supplementary Fig. 3) , it is likely that additional risk variants for multiple myeloma will be identified through further study. 
URLs

MeThOds
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
ACKNOWLEDGMENTS
We are grateful to all study participants and investigators at the individual centers for taking part. We are extremely grateful to all investigators who contributed to the generation of this data set. We also thank the staff of the Clinical Trials Research Unit (CTRU), University of Leeds, and the National Cancer Research Institute (NCRI) Haematology Clinical Studies Group. We are grateful to all investigators who contributed to the Colorectal Tumour Gene Identification (CORGI) consortium, from which controls in the replication analysis were drawn. The current study made use of genotyping data on the 1958 Birth Cohort. Genotyping data for control subjects was generated by the Wellcome Trust Sanger Institute. A full list of the investigators who contributed to the generation of the data is available from the WTCCC website (see URLs). The GWAS made use of genotyping data from the populationbased HNR study. The HNR study was supported by the HeinzNixdorf Foundation. 
AUTHOR CONTRIBUTIONS
ONLINe MeThOds
Genome-wide association studies. The UK GWAS included multiple myeloma cases (International Classification of Diseases, 10th Revision (ICD10) C90.0; 819 male; mean age at diagnosis of 64.1 years, s.d. = 10.3) ascertained through the UK MRC MyelomaIX trial 6 . All cases were UK residents. For controls, we used publicly accessible data generated by the WTCCC, the 58C (also known as the National Child Development Study) 7 and UKBS. Genotyping of both sets of controls was conducted using Illumina Human 1.2MDuo Custom_v1 Array BeadChips. SNP calling was performed using Illuminus software (see URLs). Full details of genotyping, SNP calling and quality control filtering have been previously reported (WTCCC; see URLs). Concordant with pre vious findings, comparison of the two control series showed little evidence for systematic bias (inflation factor λ = 1.019; Supplementary Fig. 1 ) 31 . The German GWAS was comprised of 384 multiple myeloma cases (ICD10 C90.0; 229 male; mean age at diagnosis of 54.5 years, s.d. = 8.0) ascertained through the Heidelberg University Centre. For controls, we used publicly accessible genotype data on 704 healthy individuals with no past history of malignancy enrolled in the HNR study 8 .
Replication. For replication, we genotyped 169 additional cases of multiple myeloma (93 male) ascertained through the UK MRC MyelomaVII trial. For controls, we made use of previously generated data from a UK GWAS of colorectal cancer (420 males, 507 females, aged from 18 to 69 years) 12 .
Ethics. Collection of blood samples and clinicopathological information from subjects was undertaken with informed consent and the approval of the relevant German or UK ethical review board, in accordance with the tenets of the Declaration of Helsinki.
Karotyping. Conventional cytogenetic studies of multiple myeloma cells were conducted using standard karotyping methodologies, and standard criteria for the definition of a clone were applied. Where possible, metaphase fluorescence in situ hybridization (FISH) was used to confirm whether abnormalities seen with immunofluorescence in situ hybridization (iFISH) were present in the same cells as the abnormalities detected by conventional cytogenetics. iFISH and ploidy classification of the UK samples was conducted as previously 33 , and iFISH and ploidy classification of the German samples was performed as described 34, 35 .
Genotyping. DNA was extracted from EDTAvenous blood samples using Qiagen FlexiGene or QIAamp methodologies and quantified using PicoGreen (Invitrogen). Genotyping of cases in the GWAS was conducted using Illumina OmniExpress BeadChips according to the manufacturer's protocols. To ensure quality of genotyping, duplicates were included on each sample plate (showing a concordance of >99.99%). DNA samples with GenCall scores <0.25 at any locus were considered to not represent calls. In each sample series, sequencing of an SNP was considered unsuccessful if <95% of DNA samples generated a genotype at the locus. Cluster plots were manually inspected for all SNPs considered for replication analysis.
Evaluation and editing cluster positions. Intensity data from arrays were imported into the Illumina BeadStudio clustering and calling software appli cation. For the small subset of loci that were not clustered properly by the automated algorithm, the data were reviewed to identify loci that needed to be removed, manually edited or left unchanged. Clustered SNPs were evalu ated using the metrics listed in the SNP table of the BeadStudio software. These metrics take into account all samples for each locus and thus provide overall performance information for each locus. To identify loci potentially needing to be edited or removed, each column in the SNP table containing a measure of the quality of the locus was sequentially sorted. Metrics used for identifying poorly or incorrectly clustered data included intensity, cluster separation, position of each cluster (AA, AB, BB), HardyWeinberg equilib rium, call frequency and variation of cluster width. The reproducibility of control samples on each plate as well as replicates was also used to identify incorrectly clustered loci. Although not all cluster plots were assessed, ~10% of the lowestperforming loci were examined. Of these, ~10-20% were edited or annotated (to indicate loci with nearby polymorphisms or hemizygous deletions), and ~2% were excluded from further analysis. Data were reviewed by a second individual to determine whether any metrics were missed or if further editing was required. Overall, this process resulted in substantially increased genotyping accuracy.
Validation of Illumina SNP genotypes.
To confirm genotyping accuracy for rs4487645, rs1052501 and rs6746082, we confirmed genotypes by ABI 3730×l Sanger sequencing in >184 randomly selected samples from each of the UK case series and the 58C and HNR control series (concordance of >99.5%). Sequences for the PCR primers used are available on request.
Replication genotyping. Replication of rs4487645, rs1052501 and rs6746082 associations were performed by ABI 3730×l Sanger sequencing of all MRC MyelomaVII trial samples.
Statistical and bioinformatic analysis. We applied predetermined quality control metrics to the GWAS data. We restricted analyses to samples for which >95% of SNPs were successfully genotyped, thus eliminating 28 cases. We computed identitybystate (IBS) probabilities for all pairs (cases and controls) to search for duplicates and closely related individuals among samples (defined as IBS ≥0.80, thereby excluding firstdegree relatives). For all identical pairs, the sample having the higher call rate was retained, eliminating 17 multiple myeloma cases. To identify individuals who might not be of Western European ancestry, we merged our case and control data with HapMap phase 2 samples (60 CEU, 60 Yoruba from Ibadan (YRI), 90 Japanese from Tokyo (JPT) and 90 Han Chinese from Beijing (CHB)). For each pair of individuals, we calcu lated genomewide IBS distances on markers shared by HapMap and our SNP panel and used these as dissimilarity measures on which to perform principal component analysis. The first two principal components for each indivi dual were plotted, and any individual not present in the main CEU cluster was excluded from analyses. We removed 35 cases with nonCEU ancestry and one 58C control who had previously been diagnosed with Hodgkin's lymphoma 31 . In each sample series, we filtered out SNPs having a minor allele frequency <1% and a call rate <95%. We also excluded SNPs showing departure from HardyWeinberg equilibrium at P < 1 × 10 −6 in controls. For replication and validation analysis, call rates were >95% per 384well plate for each SNP. Cluster plots were visually examined by two researchers.
Analyses were primarily undertaken using R (v2.6), STATA v.10 (State College) and PLINK (v1.06) 36 software. The association between each SNP and risk of multiple myeloma was assessed by the CochranArmitage trend test. The adequacy of casecontrol matching and the possibility of differential geno typing of cases and controls were formally evaluated using quantilequantile plots of test statistics. The inflation factor λ was calculated based on the 90% of SNPs with the least significant association 9 . We adjusted for possible popula tion substructure using EIGENSTRAT software. Odds ratios and associated 95% confidence intervals were calculated by unconditional logistic regres sion. Metaanalysis was conducted using standard methods 11 . We calculated Cochran's Q statistic to test for heterogeneity 11 and the I 2 statistic to quan tify the proportion of the total variation that was caused by heterogeneity 37 . I 2 values ≥75% were considered to indicate substantial heterogeneity 37, 38 . To conduct a pooled analysis incorporating EIGENSTRATadjusted P values from the GWAS, we used the weighted Z method implemented in the meta analysis helper (METAL) 39 program. Associations by sex, age and clinicopathological phenotypes were examined by logistic regression in caseonly analyses.
The familial relative risk of multiple myeloma attributable to any locus is given by the formula 40 where p is the population frequency of the minor allele, q = 1 -p, and r 1 and r 2 are the relative risks (approximated by odds ratios) for heterozygotes and the rarer homozygotes relative to the more common homozygotes. From λ*, it is possible to quantify the influence of the locus on the overall familial risk of multiple myeloma in firstdegree relatives. Assuming a multiplicative interaction between risk alleles, the proportion of the overall familial risk attributable to the locus is given by log (λ*)/log (λ 0 ), where λ 0 , the overall familial risk of multiple myeloma, is assumed on the basis of epidemiological studies to be 2.45 (ref. 5 ). The population attributable fraction was estimated from 1 -Π i (1 − x i ) − x i , where x i = p × OR pa -1)/(p × (OR pa -1) + 1), p being the frequency of the risk allele in the population and OR pa being the perallele OR.
Prediction of the ungenotyped SNPs was carried out using IMPUTEv2 based on the HapMap phase 3 haplotypes release 2 (HapMap Data Release 27, phase 3 Feb 2009 on NCBI B36 assembly, dbSNP26) and data from the 1000 Genomes Project. Imputed data were analyzed using SNPTEST v2 to account for uncertainties in SNP prediction. Measurements of LD between HapMap SNPs were based on Data Release 27, phase 3 (Feb 2009 on NCBI B36 assembly, dbSNP26), viewed using Haploview software (v4.2) and plotted using SNP annotation and proxy search (SNAP). LD blocks were defined according to HapMap recombination rate (centimorgans per megabase), as determined using the Oxford recombination hotspots 41 and the previously set distribution of confidence intervals 42 . To annotate potential regulatory sequences within disease loci, we implemented in silico searches using TRANSFAC Matrix Database v7.29 and PReMod10 software 21, 22 . We used the in silico algorithms SIFT and PolyPhen to predict the impact of amino acid substitutions on protein function.
Relationship between SNP genotype and mRNA expression.
To explore a relationship between SNP genotype and expression levels of CDCA7L, DNAH11, ULK4, TRAK1 and DTNB in multiple myeloma, we made use of Affymetrix Human Genome U133 Plus 2.0 array data we previously gener ated on the plasma cells from 192 multiple myeloma cases from the MRC MyelomaIX trial 23 . To explore a relationship between SNP genotype and expression levels in lymphocytes, we made use of publicly available expres sion data generated from the analysis of 90 lymphoblastoid cell lines derived from individuals of European descent transformed by EpsteinBarr virus using Sentrix Human6 Expression BeadChips (Illumina) 24, 25 . Online recovery of data was performed using WGAViewer Version 1.25 software. Differences in the distribution of mRNA expression levels between SNP genotypes were compared using a Wilcoxontype trend test 43 . Estimates of the power of the assays to establish a relationship between genotype and expression were made using STATA software, assuming an allelebased test of the difference in nor malized log values of RNA expression (imposing a Bonferronicorrected P value of 0.005 to address multiple testing).
